Managing Valproate-Induced Weight Gain

Introduction to Management Strategies

The American Medical Association recommends considering switching to an alternative antiepileptic drug if clinically appropriate, as valproate is among the antiepileptics most strongly associated with weight gain, or add topiramate 100 mg/day or metformin 1000 mg/day as adjunctive therapy to counteract weight gain 1, 2
Weight gain from valproate increases risk of insulin resistance, cardiovascular disease, diabetes, and hepatic steatosis, according to the American Heart Association 1, 2

Consider switching to alternative antiepileptic drugs that do not promote weight gain, such as lamotrigine, levetiracetam, or other newer agents depending on seizure type, as suggested by the American Academy of Neurology 1, 2
Topiramate 100 mg/day can be used adjunctively with weight-gain promoting medications, resulting in a mean weight reduction of 3.76 kg (95% CI: -4.92 to -2.69 kg), according to the American Medical Association 1, 2
Metformin 1000 mg total daily dose can be used adjunctively, resulting in a mean weight reduction of 3.27 kg (95% CI: -4.66 to -1.89 kg), as recommended by the American Diabetes Association 1, 2

Create a 500-750 kcal/day energy deficit through portion control and elimination of ultraprocessed foods, as suggested by the Academy of Nutrition and Dietetics 1, 2
High-protein meal replacements can be considered, resulting in a mean additional weight loss of 1.44 kg, according to the American College of Sports Medicine 1, 2
Aerobic exercise, such as 150-300 minutes/week of moderate-intensity exercise (50-70% maximal heart rate), can result in modest weight loss of 2-3 kg, as recommended by the American Heart Association 1, 2, 3

GLP-1 receptor agonists (semaglutide or liraglutide) can be considered as adjuncts to lifestyle changes, resulting in a mean weight loss of 14.9-16%, according to the American Association of Clinical Endocrinologists 1, 3, 4, 5
Dual GIP/GLP-1 receptor agonist (tirzepatide) is emerging as a highly effective option, as reported by the American Diabetes Association 5, 6

Monthly weight checks for the first 3 months, then quarterly, are recommended by the American Medical Association 1, 2
Unintentional weight gain >2 kg in the first month or ≥7% increase from baseline should trigger intervention, according to the American Heart Association 1, 2
Monitor for metabolic complications, such as fasting glucose, lipids, and liver function, as suggested by the American Association of Clinical Endocrinologists 1, 2